Beta-Adrenergic Blockers

Introduction

Beta-adrenergic blockers are a pharmacological class used in several cardiovascular and ophthalmic settings. The supplied evidence identifies established roles in ischemic heart disease, heart failure, high-risk coronary artery disease, arrhythmias, hypertension, and glaucoma, although the strength and relevance of evidence differ by indication and individual agent.^[70]D In acute myocardial infarction, beta-adrenergic blockers are associated with reductions in recurrent myocardial infarction and total mortality, while their possible direct effect on coronary atherosclerosis has been investigated separately.^[5]B2a A pooled, post hoc analysis of individual patient data from four intravascular-ultrasonography trials included 1,515 adults with coronary artery disease and evaluated whether beta-blocker therapy was associated with slower atheroma progression.^[5]B2a

Beta-blocker use is not interchangeable across clinical contexts. Traditional agents, including atenolol, have been questioned for uncomplicated hypertension because of comparatively less favorable cardiovascular-outcome evidence, whereas beta-blockers retain established importance in compelling indications such as ischemic heart disease, heart failure, arrhythmias, and high-risk coronary disease.^[70]D A French registry of 3,059 patients with myocardial infarction in its first phase and an additional 611 diabetic patients was designed to describe real-world management and outcomes, illustrating the clinical setting in which beta-blocker therapy is commonly considered, although the registry description supplied here does not establish a specific beta-blocker treatment effect.^[9]B2b

Chemical structure and pharmacological class

The references supplied for this revision do not provide compound-level chemical structures, systematic chemical names, molecular formulas, stereochemical descriptions, receptor-binding constants, or a structure-based classification of individual beta-blockers. Consequently, a definitive chemical-structure account cannot be reconstructed from the permitted evidence without introducing information from unlisted sources. The available literature supports identifying beta-blockers as agents acting within adrenergic pharmacotherapy, but it does not support assigning a universal scaffold or making compound-specific structural claims.^[3]D5[70]D

The class is discussed alongside other glaucoma-drug categories—including prostaglandin analogues, alpha-adrenergic agonists, carbonic-anhydrase inhibitors, Rho-kinase inhibitors, and cholinergic agonists—because topical beta-blockers are established options for reducing intraocular pressure.^[3]D5 The glaucoma patent review describes treatment limitations and adverse effects as factors that may impair adherence and motivate development of newer approaches, but it does not define the molecular structure of topical beta-blockers.^[3]D5

Scope of evidence relevant to the class

Clinical safety and tolerability findings are heterogeneous. A systematic review examined 24 case reports associating beta-blockers with depression and eight randomized controlled trials included in a meta-analysis of adverse effects; it abstracted the beta-blocker used, patient characteristics, depressive history, symptom type, assessment method, and assessment timing, and applied Naranjo criteria to evaluate the strength of case-report evidence.^[1]B2a This supports caution in interpreting suspected neuropsychiatric adverse effects, particularly because case reports and randomized trials may yield discrepant conclusions.^[1]B2a

In patients with prior angioedema attributed to an angiotensin-converting-enzyme inhibitor, a nationwide Danish registry cohort compared subsequent angiotensin-II receptor blockers with other antihypertensives, including beta-blockers, and with no antihypertensive therapy.^[2]B2b This study addresses comparative clinical safety in a selected population; it does not establish a chemical cross-reactivity mechanism for beta-blockers.^[2]B2b Similarly, a retrospective glaucoma chart review of 1,287 patients evaluated adverse reactions after topical carbonic-anhydrase inhibitors, prostaglandin analogues, beta-blockers, or alpha2-adrenergic agonists in people reporting sulfa allergy; its findings concern observed adverse events and do not demonstrate structural sulfonamide identity or cross-reactivity for beta-blockers.^[68]

Additional exploratory evidence suggests potential noncardiovascular effects. In 873 people with symptomatic hip and/or knee osteoarthritis and hypertension, adrenergic-blocker prescription was associated with assessment of joint pain and prescription-analgesic use; the study investigated whether use was linked to less prevalent joint pain and lower opioid requirement.^[8]B2c In streptozotocin-induced diabetic rats, propranolol was administered for 24 weeks to investigate retinal vascular endothelial growth-factor expression and retinal capillary basement-membrane thickness, alongside an angiotensin-converting-enzyme inhibitor and vehicle control.^[7]D5 These findings are mechanistic or observational and should not be generalized to all beta-blockers or directly translated into human treatment recommendations.^[7]D5[8]B2c

Finally, the supplied references address autonomic physiology, vasovagal syncope, pheochromocytoma, long-QT syndrome, and antihypertensive treatment, but they do not provide a chemical taxonomy of beta-blockers.^{[4]C4[6]B2b[10]D5[69]} In particular, the long-QT study evaluated antiseizure medications rather than beta-blockers, and the chemical-library article concerns virtual screening methodology rather than beta-blocker structures.^[6]B2b[71]D Therefore, structural claims beyond the class-level designation should be added only after verification against dedicated medicinal-chemistry references.

Core pharmacology

Beta-adrenergic blockers reduce signaling initiated by catecholamines at β-adrenergic receptors. The referenced mechanistic evidence links β-adrenergic receptor activation to adenylyl cyclase, cyclic adenosine monophosphate (cAMP), and protein kinase A (PKA) activity; therefore, receptor blockade can attenuate downstream cAMP/PKA-dependent effects. ^[72]D Because β-adrenergic receptors are distributed across multiple tissues, blockade may produce pharmacodynamic effects beyond the intended organ, a principle emphasized for ophthalmic timolol. ^[73]D

The functional consequences of β-adrenergic signaling are tissue-specific. In cardiomyocytes, β-adrenergic stimulation can modify intracellular calcium handling and electrical activity. A theoretical model of Timothy syndrome showed that enhanced sympathetic stimulation worsened arrhythmogenic behavior in cells carrying abnormal CaV1.2 channels, with progressive action-potential and QT-interval prolongation as the modeled mutant-channel burden increased. ^[16]D5 In a jellyfish-toxin cardiotoxicity model, β-blockers reduced toxin-associated intracellular calcium responses, while β-adrenergic signaling was associated with increased cAMP and PKA activity, supporting a cAMP/PKA-linked contribution to calcium dysregulation. ^[72]D

Cardiovascular remodeling

β-adrenergic blockade may influence cardiac remodeling indirectly by reducing catecholamine-driven stress signaling, although the supplied evidence does not establish a direct molecular interaction between β-blockers and transforming growth factor-β (TGF-β). TGF-β expression is increased in experimental myocardial infarction and cardiac hypertrophy and in patients with dilated or hypertrophic cardiomyopathy. ^[11]D5 TGF-β acts on cardiomyocytes, mesenchymal cells, and immune cells and contributes to cardiac fibrosis and hypertrophic remodeling. ^[11]D5 In infarcted myocardium, TGF-β deactivates inflammatory macrophages and promotes myofibroblast transdifferentiation and matrix synthesis through Smad3-dependent pathways. ^[11]D5 Accordingly, TGF-β/Smad3 signaling represents an important remodeling pathway that may be clinically relevant when considering the broader cardiovascular effects of β-adrenergic modulation, but it should not be described as a proven primary target of β-blockers on the basis of these references alone. ^[11]D5

Metabolic effects

Hepatic β-adrenergic signaling participates in age-associated lipid accumulation. In aging rats, hepatic β-adrenergic receptor levels and β-adrenergic-stimulated adenylyl cyclase activity increased, and hepatic lipid content rose during senescence; hepatic fat content significantly correlated with β-adrenergic stimulation of adenylyl cyclase. ^[15]D5 These findings support a model in which increased hepatic β-adrenergic signaling contributes to steatosis during aging, although the cited study does not define the clinical effect of a specific β-blocker or establish that blockade reverses human hepatic steatosis. ^[15]D5

β-blocker-associated metabolic effects have also been discussed in relation to insulin resistance. A hypothesis paper associated β-adrenergic blockers with insulin resistance and proposed that insulin resistance increases circulating insulin and insulin-like growth factor-1, mediators linked in that paper to proliferation, differentiation, and inhibition of apoptosis. ^[19]D5 Because this evidence is hypothesis-based, it should be treated as a proposed association rather than a confirmed universal mechanism of β-blocker therapy. ^[19]D5

Tumor biology and perioperative signaling

Catecholamine signaling can affect malignant tissues and the tumor microenvironment. In breast-cancer models and reviews, adrenergic signaling was associated with increased tumor-cell survival after chemotherapy exposure, increased proliferation, and changes in angiogenesis and inflammatory responses; retrospective evidence also linked β-blocker use in early-stage breast cancer with longer time to recurrence. ^[13]D5 These findings provide a mechanistic rationale for investigating β-adrenergic blockade as an adjunctive anticancer strategy, but they do not establish β-blockers as antineoplastic monotherapy. ^[13]D5

The perioperative period is particularly relevant because surgery and inflammation can produce sympathetic activation and release of epinephrine and norepinephrine. A review described this catecholamine surge as potentially facilitating prometastatic processes through direct effects on malignant cells and indirect regulation of immune and other components of the tumor microenvironment. ^[12]D5 The same review evaluated combined inhibition of β-adrenergic and cyclooxygenase-2 signaling as a strategy to reduce cancer recurrence, indicating that β-adrenergic blockade may be most effective in a multimodal, context-dependent approach. ^[12]D5

In a chemically induced oral-carcinogenesis model, daily subcutaneous propranolol at 10 mg/kg was administered to male Wistar rats, beginning 1 week before 4-nitroquinoline-1-oxide exposure and continuing through assessment at 16 weeks. ^[14]D5 Propranolol inhibited oral-cancer onset and reduced tumor invasion in that preclinical setting. ^[14]D5 These results support an antitumor role for β-adrenergic blockade in experimental oral carcinogenesis, but species, dose, route, tumor model, and treatment timing limit direct extrapolation to clinical cancer prevention or treatment. ^[14]D5

Drug-specific and evidence limitations

Timolol is widely used in glaucoma treatment and is included in many combined antiglaucoma preparations; its adverse effects can involve multiple organ systems because β-adrenergic receptors are broadly distributed. ^[73]D The cited pharmacogenetic review therefore supports individualized consideration of efficacy and safety, but it does not identify a single validated pharmacogenetic mechanism applicable to all patients. ^[73]D The chemical-library study described a two-dimensional virtual-screening method for finding lead-like compounds and does not provide a biological mechanism for β-blocker action. ^[71]D Overall, the supplied evidence supports β-adrenergic receptor–cAMP/PKA signaling as the central mechanistic framework, with downstream cardiovascular, metabolic, immune, and tumor-related effects varying by tissue, disease context, drug, and exposure. ^{[72]D[11]D5[15]D5[12]D5[13]D5[14]D5}

Overview

Beta-adrenergic blocker response is influenced by both disease biology and drug disposition. Persistent, adverse sympathetic outflow to the heart and kidneys is central to the pathophysiology of heart failure and essential hypertension, and beta-adrenergic blockade represents an established therapeutic translation of this mechanism in cardiac failure. ^[17]D5 These findings imply that an apparent lack of response should not automatically be interpreted as pharmacological resistance, because the clinical effect may depend on the degree and distribution of sympathetic activation, the treatment indication, drug exposure, and patient-specific pharmacology. ^[17]D5[18]D5

The supplied evidence does not establish a universal definition, numerical threshold, or validated clinical algorithm for beta-blocker resistance. ^{[17]D5[18]D5[73]D} Instead, it supports evaluating inadequate response as a potentially multifactorial phenomenon involving persistent sympathetic drive, variable plasma concentrations, altered clearance, drug interactions, organ dysfunction, and genetic variation. ^[17]D5[18]D5

Pharmacokinetic variability and pharmacogenomics

Several beta-adrenergic blockers undergo metabolism through cytochrome P450 (CYP) isoforms. ^[18]D5 CYP-dependent metabolism produces substantial interindividual variability in plasma drug concentrations, which can compromise blood-pressure reduction and clinical outcomes. ^[18]D5 Factors contributing to altered oral or systemic clearance include aging, hepatic impairment, drug–drug interactions, changes in hepatic blood supply, and genetic polymorphisms. ^[18]D5 Because the degree of blood-pressure reduction is related to antihypertensive drug exposure, differences in clearance can contribute to variable cardiovascular responses and may mimic therapeutic resistance. ^[18]D5

Pharmacogenetic considerations are particularly relevant for timolol. Timolol is described as a principal beta-blocker used in glaucoma therapy and is included in many combined ophthalmic antiglaucoma preparations. ^[73]D Although administered ophthalmically, timolol may produce systemic adverse effects because beta-adrenergic receptors are widely distributed throughout the body. ^[73]D The clinical efficacy and safety of timolol depend partly on individual characteristics, supporting a personalized approach to treatment. ^[73]D The cited pharmacogenetic review specifically frames genetic variability as relevant to timolol’s efficacy and tolerability, but the supplied evidence does not identify a single validated genotype-based dosing threshold or a universally recommended pharmacogenomic testing strategy. ^[73]D

Clinical interpretation of inadequate response

When a beta-blocker appears ineffective, assessment should account for the underlying indication. Sympathetic nervous-system dysfunction is important in both hypertension and heart failure, but the clinical translation of this mechanism is described as more mature in cardiac failure than in essential hypertension. ^[17]D5 Consequently, the expected benefit, treatment target, and interpretation of response may differ between these conditions. ^[17]D5

Drug exposure should also be considered. Reduced exposure may result from rapid metabolism associated with genetic variation, enzyme induction or inhibition, altered hepatic perfusion, hepatic disease, or age-related pharmacokinetic changes. ^[18]D5 Conversely, impaired clearance may increase exposure and adverse effects without improving the intended therapeutic response. ^[18]D5 These mechanisms are clinically important because intolerance, underdosing, nonadherence, or discontinuation may be misclassified as pharmacological resistance; however, the supplied references do not quantify the relative contribution of each mechanism. ^[18]D5[73]D

Metabolic and developmental considerations

Beta-adrenergic blockers are listed among factors associated with insulin resistance, alongside smoking, hormonal contraceptives, androgens, glucocorticoids, thiazide diuretics, high-glycaemic-index food intake, and reduced physical activity. ^[19]D5 The cited source presents insulin resistance as associated with diabetes, obesity, and metabolic syndrome and links it to increased insulin and insulin-like growth factor-1 concentrations. ^[19]D5 These observations are relevant when selecting or monitoring beta-blocker therapy in patients with metabolic disease, although the supplied evidence does not establish that beta-blocker-associated insulin resistance is a pharmacogenomic mechanism of antihypertensive resistance or provide a drug-specific risk estimate. ^[19]D5

Maternal adrenergic drug exposure may also have long-term developmental implications, but the available evidence concerns alpha1-adrenergic antagonism rather than beta-adrenergic blockade. ^[74]D In a mouse study, maternal alpha1-adrenergic antagonism during pregnancy was investigated as a potential disruptor of fetal epigenetic programming, with male offspring outcomes including dwarfism and insulin resistance. ^[74]D These findings should not be directly extrapolated to beta-blockers or to human pregnancy, but they reinforce the need to distinguish receptor class, species, developmental timing, and outcome when interpreting adrenergic-drug safety evidence. ^[74]D

Practical conclusion

The evidence supports a pharmacogenomic and pharmacokinetic framework rather than a single resistance phenotype. ^{[17]D5[18]D5[73]D} For beta-blockers, individualized assessment should consider indication, sympathetic activation, expected exposure, CYP-mediated metabolism, age, hepatic function, interacting medicines, genetic variability, systemic effects of ophthalmic timolol, and metabolic comorbidity. ^{[17]D5[18]D5[19]D5[73]D} No validated universal resistance threshold or routine genotype-guided beta-blocker protocol is established by the cited references. ^[18]D5[73]D

Scope and clinical context

Pharmacokinetics describes the sequence of liberation, absorption, distribution, metabolism, and excretion (LADME), whereas pharmacodynamics describes the physiologic response to a drug. In older adults, both pharmacokinetic and pharmacodynamic changes are clinically relevant when beta-adrenergic blockers are prescribed. ^[20]D5 The reference specifically identifies absorption, bioavailability, drug distribution, half-life, drug metabolism, and drug excretion as pharmacokinetic considerations in elderly patients receiving cardiovascular medicines, including beta-adrenergic blockers. ^[20]D5

Liberation and absorption

For orally administered beta-adrenergic blockers, liberation from the dosage form and gastrointestinal absorption are components of the overall exposure profile. ^[20]D5 Aging-related physiologic changes can alter drug absorption, although the cited source does not provide a uniform direction or numerical magnitude for these changes and does not establish a single absorption pattern applicable to every beta-adrenergic blocker. ^[20]D5 Consequently, absorption should be considered together with the individual drug’s formulation, route, and clinical response rather than inferred solely from chronological age. ^[20]D5

Bioavailability

Bioavailability determines the fraction of an administered dose that reaches the systemic circulation and is identified by the reference as an important pharmacokinetic consideration in elderly patients. ^[20]D5 Age-related changes may modify systemic exposure to cardiovascular drugs, including beta-adrenergic blockers, through effects on absorption and other pharmacokinetic processes. ^[20]D5 The cited evidence does not specify a universal bioavailability threshold, a consistent age-related increase or decrease, or drug-specific bioavailability values for beta-adrenergic blockers. ^[20]D5

Distribution

Drug distribution is an additional LADME determinant affected by aging and is relevant to cardiovascular drug therapy in older adults. ^[20]D5 Changes in body composition and other physiologic characteristics associated with aging can influence distribution and may thereby affect the concentration and persistence of a beta-adrenergic blocker; however, the supplied reference does not quantify these changes or define a common distribution pattern for the class. ^[20]D5 Distribution should therefore be interpreted alongside the agent’s physicochemical properties, dose, comorbidities, and observed tolerability. ^[20]D5

Half-life and duration of exposure

Half-life is explicitly identified as a pharmacokinetic consideration in elderly patients. ^[20]D5 Age-related alterations in distribution, metabolism, and excretion can influence drug half-life and may increase or prolong exposure to some cardiovascular medicines. ^[20]D5 The source does not provide beta-adrenergic-blocker-specific half-life values, a class-wide age-adjustment factor, or a threshold at which accumulation should be assumed. ^[20]D5 A prolonged clinical effect or adverse response should therefore prompt reassessment of dosing and organ function rather than reliance on a fixed age-based rule. ^[20]D5

Metabolism

Drug metabolism is one of the principal pharmacokinetic processes affected by aging and is relevant to beta-adrenergic-blocker therapy in older adults. ^[20]D5 Physiologic changes with aging may alter the handling of cardiovascular drugs and contribute to differences in systemic exposure between younger and older patients. ^[20]D5 The cited review does not identify a universal metabolic pathway, provide specific clearance values, or establish a single dose-reduction requirement for all beta-adrenergic blockers. ^[20]D5 Metabolic considerations must therefore remain agent-specific and should be integrated with the patient’s overall medication regimen and clinical status. ^[20]D5

Excretion

Drug excretion is also specifically identified as an age-sensitive pharmacokinetic consideration. ^[20]D5 Changes in excretory function may reduce elimination of some cardiovascular drugs, potentially increasing exposure or prolonging drug effects in older adults. ^[20]D5 The supplied reference does not provide a beta-adrenergic-blocker-specific renal threshold, clearance equation, or universal adjustment schedule. ^[20]D5 Renal and other relevant organ function should consequently be reviewed when initiating or modifying therapy, particularly when clinical effects appear excessive or prolonged. ^[20]D5

Pharmacodynamic implications of LADME changes

Pharmacokinetic changes do not operate independently of pharmacodynamics in elderly patients. ^[20]D5 Aging is associated with altered end-organ responsiveness, so the same circulating concentration may produce a different clinical effect in an older patient than in a younger patient. ^[20]D5 This interaction supports individualized prescribing, careful observation after initiation or dose changes, and attention to adverse effects rather than assuming that a standard exposure produces a standard response. ^[20]D5 The review discusses adverse effects of cardiovascular drugs in older adults and emphasizes prudent medication use, but the supplied evidence does not define a beta-adrenergic-blocker-specific adverse-effect threshold. ^[20]D5

Practical synthesis

For beta-adrenergic blockers in older adults, LADME assessment should include absorption, bioavailability, distribution, half-life, metabolism, and excretion, followed by evaluation of the patient’s end-organ response. ^[20]D5 Because the cited review provides general geriatric pharmacokinetic principles rather than drug-specific numeric parameters, dosing decisions should be individualized and guided by the selected agent, concurrent medicines, organ function, therapeutic response, and tolerability. ^[20]D5

Core pharmacology

β-Adrenergic blockers antagonize β-adrenoceptor–mediated sympathetic signaling; the clinically relevant pharmacodynamic consequences represented in the supplied evidence include attenuation of cardiac adrenergic stimulation, heart-rate reduction, suppression of adrenergically driven contractility, and reduction of sympathetic neurohormonal activity. ^[23]D5 These effects explain their use across cardiovascular disorders, although the relative contribution of receptor selectivity, dose, tissue distribution, and intrinsic vasodilator properties varies among agents and clinical settings. ^{[23]D5[29]B2a}

In chronic heart failure with reduced ejection fraction, sustained β-adrenergic blockade can improve outcomes despite the initial negative chronotropic and inotropic effects of therapy. Proposed mechanisms include neurohormonal blockade and heart-rate reduction, and landmark trials have consistently associated β-blocker treatment with lower mortality and fewer heart-failure hospitalizations. ^[23]D5 Dose response is not necessarily linear or uniform across neurohormonal antagonists; the evidence base does not establish that the highest nominal dose is always the most effective dose, and treatment is generally constrained by the maximally tolerated dose. ^[46]D5[23]D5

Dose exposure and biomarker response

In a post hoc chronic-heart-failure analysis, more than 96% of 151 participants were receiving a β-blocker at enrollment. ^[21]B2b Participants were categorized according to a final metoprolol-succinate-equivalent dose of ≥50 mg/day versus <50 mg/day, and according to soluble ST2 concentrations of ≤35 ng/mL versus >35 ng/mL. ^[21]B2b Patients with low soluble ST2 who achieved the higher β-blocker-dose category had the lowest cardiovascular-event risk, whereas the supplied abstract does not provide a complete effect estimate or establish that soluble ST2 directly mediates β-blocker benefit. ^[21]B2b

Cardiovascular electrophysiology and hemodynamics

β-Blockade reduces adrenergic acceleration of the sinus node and atrioventricular conduction, providing a pharmacodynamic basis for ventricular-rate control in atrial fibrillation; however, the supplied retrospective comparison of intravenous metoprolol and diltiazem reports comparative clinical outcomes rather than a receptor-level interaction analysis. ^[75]C In catecholaminergic polymorphic ventricular tachycardia, β-blockers are described as the drug of choice because the arrhythmia is provoked by exercise or emotional stress; incomplete control may require flecainide, device therapy, or sympathetic denervation. ^[78]D

For obstructive hypertrophic cardiomyopathy, β-blockers remain a cornerstone for symptomatic treatment, but the supplied review characterizes them as lacking disease-modifying effects. ^[76]D Cardiac myosin inhibitors reduce left-ventricular outflow-tract gradients and improve exercise capacity, functional class, and quality of life; subgroup analyses suggested that concomitant β-blockade may blunt exercise improvement, although this evidence concerns treatment strategy rather than a direct molecular antagonism. ^[76]D

β-Blockers also reduce portal-pressure responses to sympathetic stimulation and are used to monitor or modify portal hypertension. ^[77]D A reduction in hepatic venous pressure gradient of ≥20% or to <12 mmHg is associated with lower risks of bleeding or rebleeding, ascites, and spontaneous bacterial peritonitis, with improved survival reported in the cited review. ^[77]D In children with portal-vein thrombosis, β-blockers are not routinely used because efficacy is unproven and adverse effects are significant. ^[64]D5

Selectivity, population response, and skeletal effects

A systematic review concluded that patients of African ancestry generally show an attenuated antihypertensive response to β-adrenergic blockers and renin–angiotensin-system inhibitors compared with calcium-channel blockers and diuretics; the review evaluated physiologic and clinical factors associated with this differential response rather than establishing a single receptor mechanism. ^[29]B2a A meta-analysis found a 15% lower fracture risk among β-blocker users versus controls, independent of sex, fracture site, and dose; the authors suggested that β1-selective agents might contribute to this association, but the evidence was observational and assigned low evidence quality in the supplied reference. ^[28]B2a

Noncardiac and topical pharmacodynamics

Oral β-blockers may reduce rosacea-associated flushing and facial erythema, consistent with attenuation of adrenergic vasomotor responses. ^[27]B2a The systematic review included carvedilol, propranolol, nadolol, and β-blockers considered as a class, but the available abstract does not establish a definitive comparative ranking or mechanism for persistent erythema versus episodic flushing. ^[27]B2a A 78-patient comparative study evaluated propranolol, doxycycline, and their combination for rosacea, but the supplied information does not provide sufficient outcome data to define a pharmacodynamic dose-response relationship or superiority among regimens. ^[24]B2b

In ophthalmology, a 2025 component network meta-analysis evaluated topical β-adrenergic blockers among monotherapies and combinations for intraocular-pressure reduction in primary open-angle glaucoma or ocular hypertension, alongside prostaglandin analogues, EP2 agonists, α2-adrenergic agonists, and ROCK inhibitors. ^[26]A1a Its stated objective included treatment interactions, but the supplied abstract excerpt does not report the β-blocker-specific effect estimates; therefore, no quantitative ranking or interaction magnitude can be inferred here. ^[26]A1a

Perioperative and investigational context

Evidence for routine perioperative β-blockade in major noncardiac vascular surgery was specifically reviewed for effects on mortality, myocardial infarction, and other cardiovascular outcomes, but the supplied abstract does not provide the pooled estimates needed to define a pharmacodynamic benefit–risk threshold. ^[33]A1a Continuous-infusion labetalol and nicardipine have been compared retrospectively for blood-pressure management after acute stroke; this evaluates clinical administration and control rather than receptor pharmacodynamics. ^[48]B3b Dobutamine stress echocardiography studies have also examined myocardial viability while assessing the impact of β-blockers after testing, including low-, medium-, and high-dose dobutamine protocols, but the supplied abstract does not provide sufficient results to quantify β-blocker antagonism of the stress response. ^[32]A1b

Other cited evidence is indirect: intravenous cibenzoline was more successful than disopyramide for terminating postoperative paroxysmal atrial fibrillation, without testing β-blocker pharmacodynamics. ^[30]A1b β-Blockers have been used for problem behaviors in people with intellectual disabilities, but a systematic review found no randomized trials and poor overall study quality. ^[34]C4 They have also been listed among preventive options for migraine, although the cited review primarily evaluated erenumab and does not establish a β-blocker-specific efficacy estimate. ^[31]A1a Pharmacologic reviews have described β-blockers among treatments considered for phantom-limb pain, but the supplied evidence does not establish a validated β-adrenergic mechanism or clinical effect size. ^[79]D

Practical interpretation

The most consistent pharmacodynamic principle is dose-limited sympathetic antagonism: benefit depends on adequate exposure, but excessive blockade can limit tolerability and functional reserve. ^[23]D5[46]D5 Clinical interpretation should therefore distinguish mechanistic plausibility from indication-specific outcome evidence, particularly when extrapolating between heart failure, arrhythmia, portal hypertension, glaucoma, dermatology, and perioperative care. ^{[21]B2b[23]D5[26]A1a[27]B2a[33]A1a[77]D}

Cardiovascular indications

Beta-adrenergic blockers are used across several cardiovascular settings, but their benefit is disease- and population-specific. In chronic heart failure attributable to left-ventricular systolic dysfunction, higher achieved beta-blocker doses were associated with more favorable cardiovascular outcomes in a post hoc analysis of 151 patients; patients with low soluble ST2 concentrations who reached a high dose equivalent to ≥50 mg/day of metoprolol succinate had the lowest cardiovascular risk, although this observational analysis does not establish an independent dose-response treatment effect. ^[21]B2b Exercise training also improves peak oxygen consumption in heart-failure patients receiving beta-blockers; across eight prospective studies involving 236 participants, exercise increased peak VO2 by 1.27 mL/kg/min more than control, and the improvement was greater in exercising participants taking beta-blockers than in those not taking them. ^[80]

Beta-blockers are used for rate control and selected rhythm-management strategies in atrial fibrillation, but the supplied evidence does not directly evaluate beta-blocker efficacy. In postoperative paroxysmal atrial fibrillation, intravenous cibenzoline terminated arrhythmia more often than intravenous disopyramide (47% vs 24%) in a randomized study of 118 patients; these findings concern alternative antiarrhythmic therapy rather than a beta-blocker indication. ^[30]A1b

For hypertension, beta-blockers lower peripheral and central systolic blood pressure, but they may be less effective than other antihypertensive classes for central pressure reduction. In a meta-analysis of randomized trials, peripheral systolic pressure fell from 150 to 133 mmHg with nonvasodilating beta-blockers and from 145 to 134 mmHg with vasodilating beta-blockers; central systolic pressure fell from 137 to 126 mmHg and from 132 to 123 mmHg, respectively. ^[43]A1a Vasodilating beta-blockers reduced central pressure modestly more than nonvasodilating agents, but the difference was not clearly conclusive in the available evidence. ^[43]A1a Comparative evidence also raises metabolic considerations: antihypertensive treatment with angiotensin-receptor blockade has been associated with lower diabetes risk than treatment with thiazide diuretics or beta-blockers, and a crossover study in 22 hypertensive adults with abdominal obesity examined differential adipose-tissue and insulin-resistance effects of candesartan, hydrochlorothiazide, and placebo. ^[41]A1b

Beta-blockers should not automatically be selected solely for stroke prevention in hypertension. A meta-analysis of 31 randomized trials involving 273,543 participants evaluated calcium-channel blockers against placebo, beta-blockers, ACE inhibitors, and diuretics for stroke prevention, but the supplied abstract does not provide a beta-blocker-specific effect estimate. ^[44]A1a

Portal hypertension and cirrhosis

Nonselective beta-blockers reduce portal pressure and are effective for preventing variceal hemorrhage in patients with cirrhosis and gastroesophageal varices. ^[38]D5 They are not recommended to prevent the development of varices in compensated cirrhosis without varices, because a large placebo-controlled trial found no preventive benefit and a significant rate of adverse events. ^[38]D5 In a randomized trial of simvastatin for cirrhosis with portal hypertension, treatment allocation was stratified according to beta-blocker use, but the study evaluated simvastatin rather than beta-blocker efficacy. ^[36]A1b Similarly, a study of sapropterin in cirrhosis and portal hypertension assessed an alternative therapy and does not establish a beta-blocker indication. ^[37]A1b

Ophthalmic use

Topical beta-adrenergic blockers are established classes of intraocular-pressure-lowering therapy for primary open-angle glaucoma and ocular hypertension. A 2025 systematic review and component network meta-analysis evaluated beta-adrenergic blockers alongside prostaglandin analogues, nitric-oxide-donating prostaglandin analogues, EP2 agonists, rho-kinase inhibitors, unoprostone, alpha2-adrenergic agonists, and combination regimens in randomized trials of patients with primary open-angle glaucoma or ocular hypertension. ^[26]A1a The analysis was designed to compare intraocular-pressure reduction and drug interactions; treatment selection should therefore account for comparative efficacy, combinations, and interaction profiles rather than assuming that beta-blocker monotherapy is universally preferred. ^[26]A1a

Perioperative and diagnostic use

Routine perioperative beta-blocker initiation for major noncardiac vascular surgery should not be assumed to reduce mortality or myocardial infarction. A Cochrane review evaluated perioperative beta-blockade for these outcomes and other cardiovascular safety endpoints, reflecting uncertainty about broad prophylactic use in patients undergoing major vascular surgery. ^[33]A1a In elderly surgical patients already receiving beta-blockers, cardiovascular signs of inadequate anesthesia may be masked; a randomized trial therefore evaluated processed-EEG-guided sevoflurane titration after at least 24 hours of preoperative beta-blocker therapy. ^[40]A1b Beta-blockade also affects pharmacologic stress testing: a 2025 study of 189 patients with ischemic cardiomyopathy assessed myocardial viability during dobutamine stress echocardiography at 10, 20, and 30 µg/kg/min, with beta-blockers administered after the examination, so these data do not support withholding or prescribing beta-blockers as a treatment indication. ^[32]A1b

Other proposed or adjunctive uses

Beta-blockers have been studied for vasovagal syncope, migraine prevention, infantile hemangioma, Marfan syndrome, fracture risk, and cancer outcomes, but the supplied evidence supports different levels of use. In a meta-analysis of vasovagal syncope treatments, beta-blockers were not effective when analysis was restricted to randomized comparisons with nonpharmacologic therapy, whereas alpha-adrenergic agonists reduced recurrence. ^[42]B2a Beta-blockers are listed among preventive options for migraine, but the supplied 2025 evidence evaluates erenumab and does not establish beta-blocker efficacy. ^[31]A1a Oral propranolol was more effective than comparator treatments for infantile hemangioma in a meta-analysis of 61 studies involving 5,130 participants, supporting propranolol as a clinically important treatment option in that condition. ^[45]B2a Beta-blockers are commonly used in Marfan syndrome to reduce hemodynamic stress related to aortic-root dilation, while nebivolol has been proposed as a vasodilating alternative; the cited Marfan publication is a trial rationale and design, not an outcome study. ^[39]D5 Observational meta-analysis found approximately 15% lower fracture risk among beta-blocker users, potentially related to beta1-selectivity, but this evidence is not sufficient to prescribe beta-blockers for fracture prevention. ^[28]B2a A mixed-treatment analysis of antihypertensive randomized trials evaluated cancer incidence, but the supplied abstract does not establish a clinically actionable cancer-prevention or cancer-treatment indication for beta-blockers. ^[35]A1a

General principles

Dose selection for β-adrenergic blockers is indication-specific, and the references supplied do not support a single universal starting dose, target dose, or maximum dose for the class. Recommendations may differ between clinical guidelines, product labeling, reference texts, and prescribing practice. ^[50]D5 In chronic heart failure with reduced ejection fraction (HFrEF), β-blockers are used as neurohormonal therapy and have been associated with reductions in mortality and heart-failure hospitalization; however, the dose achieved in clinical trials has not always matched the dose achieved in routine practice. ^[23]D5 There is also no consensus regarding the efficacy of low doses or the precise shape of the dose–response relationship for neurohormonal antagonists in chronic heart failure. ^[46]D5

Chronic heart failure

β-blocker therapy should be titrated toward the highest dose that the patient can tolerate rather than stopped solely because a guideline-trial target cannot be reached. The concept of a “maximally tolerated β-blocker dose” is clinically important but incompletely defined, and evidence indicates room for improvement in achieving this dose in patients with heart failure. ^[23]D5 Dose escalation should therefore be individualized according to tolerability and the clinical context; the supplied references do not provide a drug-specific titration schedule. ^[23]D5[46]D5

In a post hoc analysis of 151 patients with heart failure attributable to left-ventricular systolic dysfunction, more than 96% were receiving a β-blocker at enrollment. ^[21]B2b Final dose was expressed as a metoprolol-succinate-equivalent daily dose, with ≥50 mg/day classified as high dose and <50 mg/day classified as low dose. ^[21]B2b Patients with low soluble ST2 concentrations (≤35 ng/mL) who were titrated to the high-dose category had the lowest cardiovascular-event burden in the reported analysis. ^[21]B2b These findings support achieving a tolerated higher dose when clinically appropriate, but they are post hoc and do not establish that a fixed 50-mg/day threshold is an appropriate target for every β-blocker or every patient. ^[21]B2b

Dose-response evidence should not be interpreted as requiring maximal dosing in patients who develop clinically important intolerance. The cited literature emphasizes the distinction between a nominal trial target and the maximally tolerated dose in real-world heart-failure care. ^[23]D5 The supplied evidence does not specify dose-adjustment rules for hypotension, bradycardia, congestion, renal dysfunction, or other adverse effects; therefore, those decisions require product-specific prescribing information and clinical judgment, which are outside the references provided here. ^[23]D5[46]D5

Acute blood-pressure control after stroke

Continuous-infusion labetalol and nicardipine are both used for elevated blood pressure after acute ischemic stroke or intracerebral hemorrhage. ^[48]B3b A retrospective cohort study compared these agents with respect to time spent within the target blood-pressure range, time to reach target, number of dose adjustments, and use of rescue therapy. ^[48]B3b Because the cited abstract does not provide the infusion concentrations, starting rates, titration increments, or maximum rates, those administration parameters should not be inferred from this study. ^[48]B3b

Temporary pacing and interruption of therapy

When atrioventricular block occurs in a patient receiving an atrioventricular-node-blocking drug, temporary pacing may be used while the suspected drug therapy is discontinued and the rhythm is observed. ^[49]C4 In the reported retrospective study, discontinuation of drug therapy was evaluated for its effect on the subsequent need for permanent pacemaker implantation. ^[49]C4 This evidence concerns management of suspected drug-associated conduction disease and should not be interpreted as a routine recommendation to withdraw β-blockers in stable patients. ^[49]C4

Doses in related or nontherapeutic settings

In a stress-echocardiography study of patients with ischemic cardiomyopathy, dobutamine was administered at 10, 20, or 30 µg/kg/min in low-, medium-, and high-dose groups, respectively; β-blockers were administered 1 minute after the dobutamine stress examination. ^[32]A1b These doses describe a diagnostic stress protocol and are not therapeutic β-blocker dosing recommendations. ^[32]A1b

Sapropterin, not a β-blocker, was studied in cirrhosis with portal hypertension at 5 mg/kg/day, increased to 10 mg/kg/day on day 8, for a two-week treatment period. ^[37]A1b This regimen should not be used to guide β-blocker administration. ^[37]A1b

Available meta-analytic evidence found approximately 15% lower fracture risk among β-blocker users compared with controls, independent of gender, fracture site, and dose; the authors suggested that β1-selective agents might contribute to this association. ^[28]B2a This observationally informed outcome does not establish a dose for fracture prevention or justify altering β-blocker therapy for that purpose. ^[28]B2a Experimental exposure data for propranolol and metoprolol in Daphnia magna concern environmental toxicity and have no application to human dosing. ^[47]D5

Practical summary

Use indication-specific, product-specific dosing; titrate chronic heart-failure therapy toward the highest tolerated dose; interpret ≥50 mg/day metoprolol-succinate equivalent only as the threshold used in one post hoc analysis; and avoid extrapolating diagnostic, environmental, or non-β-blocker dosing studies to routine β-blocker treatment. ^{[21]B2b[23]D5[32]A1b[37]A1b[46]D5[47]D5}

Scope and evidence limitations

Dose modification should be individualized according to indication, clinical response, adverse effects, hemodynamics, and the specific β-blocker formulation; however, the supplied references do not provide a current, drug-specific titration schedule for hypertension, angina, arrhythmia, or heart failure. ^{[23]D5[46]D5[50]D5} The strongest directly relevant clinical evidence concerns chronic heart failure with left ventricular systolic dysfunction, whereas several other references address fracture risk, experimental pharmacology, environmental exposure, portal hypertension, or dobutamine stress testing rather than routine β-blocker dose adjustment. ^{[21]B2b[28]B2a[32]A1b[37]A1b[47]D5[81]D[92]D}

Heart failure: target the maximally tolerated dose

β-blockers reduce mortality and heart-failure hospitalization in chronic heart failure with reduced ejection fraction, and dose escalation is generally considered within a strategy of neurohormonal blockade when tolerated. ^[23]D5 Nevertheless, the definition of a “maximally tolerated β-blocker dose” is incompletely standardized, and published heart-failure trials achieved different doses from routine clinical practice. ^[23]D5 The presence of a maximally tolerated dose should therefore not be assumed solely from failure to reach a trial target; it reflects the highest dose that can be maintained safely for the individual patient. ^[23]D5

The dose–response relationship is uncertain. A review of placebo-controlled and active-comparator heart-failure trials reported no consensus regarding the efficacy of low doses or the shape of the dose–response curve for neurohormonal antagonists. ^[46]D5 Accordingly, a lower tolerated dose may still provide treatment exposure, but the supplied evidence does not establish an equivalent clinical benefit between low and target doses. ^[46]D5

In a post hoc analysis of 151 patients with heart failure attributable to left ventricular systolic dysfunction, more than 96% were receiving a β-blocker at enrollment and medication regimens were assessed over 10 months. ^[21]B2b Final β-blocker exposure was categorized as high at ≥50 mg/day metoprolol-succinate equivalent and low at <50 mg/day; soluble ST2 was categorized as low at ≤35 ng/mL or high at >35 ng/mL. ^[21]B2b Patients with low baseline soluble ST2 who achieved the high-dose category had the lowest cardiovascular-event burden in the reported analysis. ^[21]B2b These findings are post hoc and biomarker-stratified; they support investigation of dose achievement in appropriate patients but do not establish a universal dose threshold or justify escalation without regard to tolerability. ^[21]B2b

Practical modification principles supported by the evidence

Dose recommendations can differ substantially between guideline sources, package inserts, prescribing references, textbooks, and clinical practice. ^[50]D5 A 2006 analysis found that beginning-dose recommendations for antihypertensive drugs differed between the Joint National Committee guidance and product-reference sources, and that handheld prescribing programs and textbooks did not consistently reproduce either recommendation. ^[50]D5 Thus, the product-specific prescribing information and indication-specific guideline should be checked before altering a dose. ^[50]D5

The evidence supplied does not support routine dose reduction solely to prevent fractures. A meta-analysis reported a 15% lower fracture risk among β-blocker users than controls, independent of gender, fracture site, and dose; the authors suggested that β1-selective agents might contribute to this association. ^[28]B2a This observationally informed meta-analytic result is not a dose-modification rule and should not override cardiovascular tolerability or indication-specific requirements. ^[28]B2a

Situations not establishing routine dose changes

A dobutamine stress-echocardiography study in 189 patients with ischemic cardiomyopathy compared dobutamine doses of 10, 20, and 30 µg/kg/min and administered β-blockers 1 minute after the examination. ^[32]A1b These procedural doses and timing relate to stress testing, not chronic β-blocker titration, and should not be transferred to outpatient dose modification. ^[32]A1b

A randomized study of sapropterin in cirrhosis and portal hypertension evaluated sapropterin at 5 mg/kg/day, increased to 10 mg/kg/day on day 8, rather than β-blocker therapy; it therefore provides no basis for modifying β-blocker doses. ^[37]A1b Experimental exposure of Daphnia magna to propranolol or metoprolol and laboratory studies of newly synthesized adrenergic blockers likewise do not provide human dosing guidance. ^[47]D5[81]D Carvedilol inhibition of cloned Kv1.5 channels occurred in vitro with a reported IC50 of 2.56 µM, but this concentration-dependent electrophysiologic observation is not a clinical dose-adjustment threshold. ^[92]D

Summary

Escalate β-blocker therapy in chronic heart failure only when the patient can tolerate further treatment, using the drug-specific regimen and monitoring framework applicable to the indication. ^[23]D5[46]D5 Do not interpret ≥50 mg/day metoprolol-succinate equivalent as a universal target, because that threshold came from a post hoc analysis and not a prospective titration trial. ^[21]B2b Avoid dose changes based solely on fracture concerns, laboratory ion-channel findings, environmental studies, or procedural dobutamine protocols. ^{[28]B2a[32]A1b[47]D5[92]D}

Overview

Beta-adrenergic blocker toxicity is primarily pharmacodynamic, reflecting excessive β-adrenergic antagonism: clinically important concerns include bradycardia, atrioventricular (AV) block, hypotension, falls, bronchospasm, impaired recognition or treatment of anaphylaxis, neuropsychiatric symptoms, and fetal growth effects. The supplied evidence evaluates these risks across randomized trials, systematic reviews, observational cohorts, perioperative studies, pregnancy, dermatology, ophthalmology, and environmental toxicology rather than through a single class-wide safety analysis ^{[1]B2a[2]B2b[27]B2a[33]A1a[49]C4[53]B2b[58]B2b[83]C[85]C}.

Cardiovascular and hemodynamic toxicity

Bradycardia and excessive AV-nodal suppression are clinically important class effects. In a retrospective study of patients receiving temporary pacing for AV block, discontinuation of AV-nodal-blocking drugs was specifically evaluated to determine whether permanent pacing could be avoided, supporting medication-related conduction disease as a potentially reversible contributor in selected patients ^[49]C4. The abstract does not provide the proportion whose conduction recovered, so a quantitative recovery estimate cannot be inferred ^[49]C4.

Perioperative use requires particular caution. A Cochrane systematic review assessed perioperative β-blockade for major vascular surgery and included mortality, myocardial infarction, and cardiovascular safety outcomes, but the supplied abstract does not report pooled adverse-event estimates ^[33]A1a. Studies of postoperative atrial fibrillation addressed prevention and treatment contexts rather than establishing β-blocker toxicity rates: one systematic review evaluated prophylactic therapies after cardiac surgery in patients with diabetes mellitus ^[52]A1a, while a prospective study associated baseline renal function with postoperative atrial fibrillation ^[82]C and another associated postoperative leukocytosis with this complication ^[84]. These studies should not be interpreted as evidence that β-blockers cause postoperative atrial fibrillation ^{[52]A1a[82]C[84]}.

In cirrhosis, nonselective β-blockers lower portal pressure and prevent variceal hemorrhage, but a large multicenter placebo-controlled trial found no benefit for preventing variceal development and reported a significant rate of adverse events; use is therefore not recommended in compensated cirrhosis without varices ^[38]D5. A randomized trial of simvastatin in cirrhosis stratified randomization according to concurrent β-blocker treatment and evaluated safety, but the supplied abstract does not identify β-blocker-specific adverse outcomes ^[36]A1b.

Initiation of antihypertensive therapy, including β-blockers, was associated with a significant increase in falls among adults aged ≥66 years during the first 14 days after treatment initiation in a population-based self-controlled case-series study ^[85]C. This finding supports heightened orthostatic and fall-risk surveillance during early treatment, particularly in older adults ^[85]C.

Respiratory, allergic, and dermatologic concerns

β-blockers have been associated with concern about more severe anaphylactic reactions, including reactions to contrast media. In a matched observational study of cardiac catheterization, investigators assessed anaphylactic-reaction risk in patients receiving β-blockers or ACE inhibitors in the era of low-osmolar contrast and cardioselective β-blockers; the supplied abstract does not provide the adjusted risk estimate ^[83]C. Accordingly, the reference supports risk assessment but not a definitive class-wide magnitude of risk ^[83]C.

A systematic review of oral β-blockers for rosacea-associated flushing and erythema included nine studies involving carvedilol, propranolol, nadolol, or β-blockers generally; the supplied abstract does not report the adverse-event results ^[27]B2a. A separate retrospective ophthalmology study evaluated adverse reactions to topical glaucoma medications, including topical β-blockers, in patients with self-reported sulfonamide allergy; increased reactions in such patients were reported for topical antiglaucoma medications generally, but the abstract does not establish a β-blocker-specific sulfonamide cross-reactivity signal ^[68].

Neuropsychiatric effects

The relationship between β-blockers and depression is inconsistent. A systematic review compared 24 case reports describing an association with depression against 8 randomized controlled trials included in a prior meta-analysis of adverse effects ^[1]B2a. The review extracted drug, demographic, diagnostic, symptom, assessment, and timing data and applied Naranjo criteria to evaluate causality, highlighting that spontaneous case reports and randomized trial findings may differ in strength and susceptibility to bias ^[1]B2a. The available abstract does not establish a definitive causal class effect or quantify excess depression risk ^[1]B2a.

Pregnancy and fetal effects

Fetal growth restriction (FGR) is a potential pregnancy-related safety concern. In a retrospective study of 158 pregnancies complicated by maternal cardiovascular disease, FGR occurred in 26% of pregnancies exposed to β-adrenergic blockers, compared with 7% with carvedilol and 3% in controls; the between-group difference was statistically significant ^[58]B2b. Because this was a single-center retrospective study, the association may reflect confounding by maternal disease or treatment indication, and it does not establish causality ^[58]B2b. A newer retrospective cohort examined gestational weight gain in pregnancies with chronic hypertension treated with β-blockers or calcium-channel blockers versus unmedicated pregnancies, but the supplied abstract does not report the comparative results ^[53]B2b.

Evidence boundaries and nonhuman toxicity

Several cited studies are indirect or do not provide β-blocker-specific toxicity estimates. A prospective comparison of intravenous cibenzoline and disopyramide treated postoperative paroxysmal atrial fibrillation rather than evaluating β-blocker toxicity ^[30]A1b. A retrospective comparison of continuous-infusion labetalol and nicardipine after stroke evaluated safety, efficacy, and administration, but the supplied abstract does not report the safety findings ^[48]B3b. A registry study primarily examined angiotensin-receptor-blocker safety after ACE-inhibitor angioedema and included β-blockers as comparator antihypertensives, without a β-blocker-specific result in the supplied abstract ^[2]B2b. In environmental testing, propranolol and metoprolol produced concentration-dependent effects in Daphnia magna; 9-day growth-effect concentrations were 0.44 mg/L for propranolol and 12 mg/L for metoprolol, while fecundity-effect concentrations were 0.11 mg/L and 6 mg/L, respectively, and these findings cannot be directly extrapolated to human therapeutic toxicity ^[47]D5.

Overview

Beta-adrenergic blockers have clinically important pharmacodynamic interactions with drugs that alter vascular tone, cardiac conduction, airway reactivity, renal sodium handling, neuromuscular transmission, or serum potassium. The magnitude of interaction depends on the specific beta-blocker, beta-1 selectivity, dose, route, patient age, hepatic function, renal function, and metabolic phenotype. ^{[18]D5 [20]D5 [61]D5}

Nonsteroidal anti-inflammatory drugs

Ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect of beta-adrenergic blockers. Cyclooxygenase inhibition decreases synthesis of inflammatory and vasodilatory prostaglandins; reduced renal blood flow and impaired renal excretion of sodium and water are proposed mechanisms. ^[60]D5 The interaction is usually small in terms of blood-pressure change, but clinically relevant elevations may occur in some patients. ^[60]D5 It generally requires more than 5 days of combined treatment to become apparent. ^[60]D5

Monitor blood pressure when ibuprofen is initiated, particularly in patients receiving beta-blockers for hypertension or with other cardiovascular risk factors. ^[60]D5 The cited evidence concerns ibuprofen and antihypertensive therapy in dental practice and does not establish that every NSAID, beta-blocker, or treatment duration produces the same degree of interaction. ^[60]D5

Calcium-channel blockers and other cardiovascular drugs

Beta-blockers are used with calcium-channel antagonists and other antihypertensive drugs, but clinically important interaction risk is influenced by pharmacokinetic and pharmacodynamic factors. ^[18]D5 Additive effects on blood pressure or cardiac function should be considered when antihypertensive regimens are intensified, especially in older adults, who have altered drug absorption, distribution, metabolism, excretion, and end-organ responsiveness. ^[20]D5

Many beta-blockers and related antihypertensive agents undergo hepatic metabolism through cytochrome P450 isoforms. CYP-dependent clearance produces substantial interindividual variation in plasma concentrations and treatment response; aging, hepatic impairment, altered hepatic blood flow, drug interactions, and genetic polymorphisms can further change exposure. ^[18]D5 Nebivolol is a third-generation beta-adrenergic blocker with pharmacologic and pharmacokinetic characteristics that should be considered when assessing combination therapy and patient-specific exposure. ^[61]D5

Bronchodilators and pulmonary therapy

Beta-blockers may cause bronchoconstriction, with the theoretical risk greatest for non-beta-1-selective agents. ^[87]D This is particularly relevant in patients with chronic obstructive pulmonary disease (COPD), in whom long-acting beta-agonists (LABAs) are used to improve lung function, dyspnea, and quality of life. ^[87]D Available clinical experience supports considering beta-blocker therapy in patients with heart failure and COPD because beta-blockers improve morbidity and mortality in heart failure populations with and without COPD; however, pulmonary symptoms and airway response require monitoring. ^[87]D

The combination of a beta-blocker with a LABA is pharmacologically plausible in selected patients, but beta-blocker selectivity and the balance between cardiac benefit and possible bronchoconstriction should guide treatment. ^[87]D

Succinylcholine and potassium-related risk

Succinylcholine and beta-adrenergic blockers can both contribute to hyperkalemia. ^[86]C A reported fatal case involved life-threatening hyperkalemia after succinylcholine administration in a 14-year-old girl receiving oral propranolol. ^[86]C This case does not establish the frequency of the interaction, but it demonstrates the potential severity in susceptible patients. ^[86]C

Before emergency or elective anesthesia, identify beta-blocker therapy and assess other hyperkalemia risks when feasible. Anesthesiology teams should consider perioperative potassium monitoring and heightened vigilance after succinylcholine in patients receiving beta-blockers, particularly when additional risk factors are present. ^[86]C

Prostaglandin and ophthalmic therapy

A 2025 systematic review and component network meta-analysis evaluated intraocular-pressure-lowering monotherapies and combinations in primary open-angle glaucoma or ocular hypertension, including prostaglandin F2-alpha analogs, nitric-oxide-donating prostaglandin analogs, EP2 agonists, unoprostone, alpha-2 adrenergic agonists, beta-adrenergic blockers, rho-kinase inhibitors, and combination therapies. ^[26]A1a The review specifically addressed comparative efficacy and drug interactions involving newer EP2 agonists, rho-kinase inhibitors, and combination regimens. ^[26]A1a Because the supplied abstract does not report the interaction estimates or identify a specific beta-blocker interaction, no drug-specific conclusion should be inferred from this citation alone. ^[26]A1a

Experimental and perioperative combination findings

In a hamster model of liver cirrhosis, curcumin was studied with alpha- and beta-adrenergic antagonists, including carvedilol, in relation to Nrf-2 and NF-kappa-B pathways. ^[59]D5 These experimental findings should not be extrapolated directly to clinical drug-interaction recommendations in humans. ^[59]D5

A perioperative oncology review described combined inhibition of beta-adrenergic and cyclooxygenase-2 signaling as a strategy targeting catecholamine- and inflammation-associated prometastatic processes around cancer surgery. ^[12]D5 This is a mechanistic and investigational framework rather than evidence that routine beta-blocker plus COX-2-inhibitor treatment is indicated for cancer prevention. ^[12]D5

Cardiac myosin inhibitors

Beta-blockers remain among standard symptomatic treatments for hypertrophic cardiomyopathy, alongside calcium-channel blockers and disopyramide. ^[62]D5 Mavacamten and aficamten are newer selective cardiac myosin inhibitors whose disposition involves CYP450 enzymes; CYP activity, drug interactions, and genetic polymorphisms are therefore clinically relevant to their use. ^[62]D5 The cited review focuses on myosin-inhibitor pharmacokinetics and does not establish a specific beta-blocker interaction. ^[62]D5

Practical monitoring

Review all prescription, over-the-counter, and perioperative medicines before starting or changing a beta-blocker. Monitor blood pressure after prolonged ibuprofen exposure, respiratory status in COPD or asthma-prone patients, cardiac response when combining cardiovascular agents, and potassium risk before succinylcholine. ^{[60]D5 [86]C [87]D} Reassess interaction risk when hepatic impairment, advanced age, or pharmacogenetic variability may alter beta-blocker exposure. ^{[18]D5 [20]D5}

Scope and evidence limitations

Beta-adrenergic blockers require individualized risk–benefit assessment in special populations because the available evidence is heterogeneous, ranging from a mechanistic animal study and a single-patient report to retrospective cohorts, narrative reviews, and trial protocols ^{[63]D5[53]B2b[58]B2b[88]C[89]D}. The supplied references do not establish a universal contraindication applicable to every beta-blocker or every clinical setting; instead, they identify populations in which efficacy may be uncertain, adverse effects may be clinically important, or additional monitoring is warranted ^{[63]D5[58]B2b[64]D5[89]D}.

Catecholaminergic polymorphic ventricular tachycardia

In catecholaminergic polymorphic ventricular tachycardia (CPVT), physical or emotional stress can provoke lethal ventricular arrhythmias through spontaneous calcium release and delayed after-depolarizations ^[63]D5. Beta-adrenergic blockers are described as the therapy of choice, but they may fail to control arrhythmia in up to 50% of patients ^[63]D5. This limitation is particularly relevant to recessively inherited CPVT caused by calsequestrin (CASQ2) mutations, for which Katz et al. evaluated treatment optimization in CASQ2-mutant mice using telemetry at rest, during treadmill exercise, and after epinephrine administration, followed by validation in human patients ^[63]D5. Adult CASQ2-mutant mice demonstrated complex ventricular arrhythmia at rest and developed bidirectional and other stress-associated ventricular arrhythmias during testing ^[63]D5.

Failure of beta-blocker monotherapy should therefore not be interpreted as evidence that adrenergic suppression is unnecessary in CPVT; it indicates the need for specialist reassessment and consideration of optimized antiarrhythmic therapy based on phenotype and genotype ^[63]D5. The cited study supports treatment optimization in CASQ2-related disease but does not provide a general contraindication to beta-blocker use in CPVT ^[63]D5.

Pregnancy and fetal growth

Pregnancy is a special population in which fetal growth should be monitored when beta-adrenergic blockers are used for maternal cardiovascular disease ^[58]B2b. In a retrospective single-center review of 158 pregnancies, fetal growth restriction (FGR) occurred in 26% of pregnancies exposed to a beta-adrenergic blocker, compared with 7% in the carvedilol alpha/beta-blocker group and 3% in the control group; the abstract reports a significant difference in FGR incidence between groups ^[58]B2b. Maternal outcomes were not significantly different among the carvedilol, beta-blocker, and control groups in that study ^[58]B2b.

These findings are observational and do not prove that beta-blockers caused FGR or that carvedilol is safer than other agents, because treatment assignment and underlying cardiovascular disease may differ between groups ^[58]B2b. Nonetheless, fetal growth surveillance and obstetric–cardiology coordination are prudent when treatment is clinically indicated ^[58]B2b.

A newer retrospective cohort study examined gestational weight gain in pregnancies complicated by chronic hypertension treated with beta-adrenergic blockers or calcium-channel blockers versus unmedicated pregnancies ^[53]B2b. The investigators used the PeriBank database, excluded pregnancies with factors affecting gestational weight gain, and calculated expected weight gain according to maternal body mass index and gestational age at delivery ^[53]B2b. The supplied abstract does not report the comparative outcome data; therefore, it cannot establish whether beta-blocker treatment increases excessive or insufficient gestational weight gain ^[53]B2b.

Children and portal hypertension

Beta-adrenergic blockers are not routinely used in children with portal hypertension caused by portal vein thrombosis because efficacy remains unproven and adverse effects are considered significant ^[64]D5. In this setting, endoscopic approaches—including sclerotherapy and endoscopic variceal ligation—are described as effective for acute variceal bleeding and variceal eradication, with endoscopic variceal ligation identified as the preferred treatment because of minimal complications and the need for few sessions ^[64]D5. Thus, pediatric portal hypertension associated with portal vein thrombosis should not be managed by automatically extrapolating adult beta-blocker practice ^[64]D5.

Genetic aortopathy

In Marfan syndrome with FBN1 mutations, aortic-root aneurysm is the major cardiovascular problem, with dissection risk reported when the aortic-root diameter approaches 5 cm ^[39]D5. Beta-adrenergic blockers are described as the drugs most commonly used in Marfan syndrome ^[39]D5. The cited trial rationale compares losartan, nebivolol, and their combination for progression of aortic-root dilation; nebivolol is characterized as a third-generation beta-blocker that retains heart-rate effects and may also exert antistiffness effects ^[39]D5. The reference is a trial design paper, not definitive comparative-outcome evidence, so it does not establish superiority of nebivolol, losartan, or combination therapy ^[39]D5.

Metabolic, neurologic, sleep, and allergic considerations

A medical-hypothesis article lists beta-adrenergic blockers among factors associated with insulin resistance, alongside diabetes, obesity, metabolic syndrome, smoking, hormonal contraceptives, and other exposures ^[19]D5. Because this is a hypothesis-based publication rather than a clinical outcomes study, it should not be used alone to contraindicate beta-blockers; it supports attention to metabolic risk in susceptible patients ^[19]D5.

A systematic-review protocol concerning pharmacologic treatment of agitation after traumatic brain injury notes that benefits, safety, interactions, and possible cognitive effects of proposed agents remain uncertain ^[54]D5. It does not establish a beta-blocker-specific recommendation or contraindication ^[54]D5. A case report described successful treatment of sleep problems in a 2-year-old girl with Smith–Magenis syndrome using melatonin and beta-adrenergic blockers, but this single case cannot establish routine pediatric efficacy or safety ^[88]C.

Anaphylaxis requires particular caution in “risky populations,” including infants and older adults, although the supplied review emphasizes delayed recognition and heterogeneous severity rather than providing a beta-blocker-specific contraindication or treatment algorithm ^[89]D. A trauma-center pharmacoepidemiologic study assessed medications administered to adolescents and adults after physical injury and medications prescribed at surgical discharge, but the supplied abstract does not provide beta-blocker-specific findings ^[65]B2c.

Perioperative monitoring during beta-adrenergic blockade

Beta-blockade can blunt the usual cardiovascular responses to inadequate general anesthesia, making heart rate and blood pressure less reliable as sole indicators of anesthetic depth in older surgical patients. ^[40]A1b In a blinded, randomized clinical trial, patients aged >65 years who had received beta-adrenergic blockers for at least 24 hours before non-cardiac surgery were assigned to sevoflurane titration guided either by a processed electroencephalogram (EEG) monitor or by standard clinical assessment. ^[40]A1b The trial specifically evaluated whether processed-EEG guidance could shorten time to extubation in this beta-blocked population. ^[40]A1b

Processed EEG may therefore be considered an adjunct when cardiovascular signs are masked by beta-blocker therapy, rather than relying on hemodynamic responses alone. ^[40]A1b The rationale for using processed EEG is that it has been reported to help reduce anesthetic drug administration, optimize emergence, and, in some studies, reduce awareness; these statements describe the background evidence cited by the trial rather than a universal treatment effect. ^[40]A1b The supplied abstract does not provide the randomized trial’s outcome data, so no definitive conclusion about extubation benefit, anesthetic dose reduction, or awareness prevention can be drawn from the available information. ^[40]A1b

Several processed-EEG systems may produce different indices from the same EEG signal. An offline comparison in older surgical patients evaluated the SedLine Root patient state index, bilateral BIS VISTA bispectral index, and the Datex-Ohmeda S/5 Entropy module using a playback system that simultaneously replayed pre-recorded EEG signals into the devices. ^[67]D5 This methodology supports caution when interpreting numerical values across devices: a displayed index should be interpreted according to the specific monitor and clinical context, not assumed to be interchangeable with another device’s score. ^[67]D5 The supplied abstract does not report the comparative performance results, so device-specific superiority or equivalence cannot be established from this reference. ^[67]D5

Adherence and preoperative review

Medication reconciliation should explicitly assess whether prescribed outpatient beta-blocker therapy is actually being taken before surgery. In a prospective observational study of veterans presenting for surgery, 14.1% of participants who presented for surgery were nonadherent to preoperative beta-blocker therapy, with a 95% confidence interval of 7%–21%. ^[90]C Nonadherence was reported in 9.5% of participants without depression and 27.8% of those with mild depression symptoms. ^[90]C Depression symptom severity, distressed personality characteristics, and beta-blocker nonadherence were the prespecified associations investigated in the study. ^[90]C

The adherence review should therefore include a direct medication history and screening for barriers such as depressive symptoms when clinically appropriate. ^[90]C This study was conducted in a veterans hospital and included 120 patients on outpatient beta-blocker therapy, although only 99 presented for surgery and contributed to the reported adherence estimate. ^[90]C The observational design demonstrates an association and prevalence estimate, not that depression causes nonadherence or that screening improves perioperative outcomes. ^[90]C

Follow-up in critical illness and autonomic dysfunction

In multiple organ dysfunction syndrome (MODS), autonomic function may be followed with heart-rate-variability (HRV) assessment. A retrospective analysis included 157 patients with MODS, defined in the report as failure of two or more organ systems, and analyzed 24-hour Holter ECG recordings obtained within the first 48 hours of illness. ^[91]D Beta-adrenergic-blocker exposure, autonomic dysfunction, HRV, and 28-day mortality were evaluated. ^[91]D MODS was described as having a high mortality of approximately 40%–60% in the study background. ^[91]D

Because the supplied abstract does not include the complete results, it does not establish that beta-blockers improve HRV, autonomic balance, or survival in MODS. ^[91]D HRV and beta-blocker exposure should consequently be treated as observational monitoring variables in this evidence set, not as validated targets for initiating, escalating, or discontinuing therapy. ^[91]D

Long-term disease surveillance

A retrospective active-surveillance study evaluated whether atenolol exposure was associated with pathological upgrading in men with low-risk or favorable intermediate-risk prostate cancer. ^[66]B2b Men entered surveillance between 2006 and 2020 across three urban hospitals, and the exposure was duration of atenolol use; the outcome was upgrading to pathological grade group ≥3 on final biopsy. ^[66]B2b Cox proportional-hazards regression was used to examine the association. ^[66]B2b The available abstract does not report the hazard estimates or conclusions; therefore, atenolol should not be started, stopped, or continued solely to alter prostate-cancer upgrading risk on the basis of this reference. ^[66]B2b

Practical interpretation

Monitoring should be individualized to the indication, with particular attention to masked anesthetic signs, medication adherence, autonomic status in critical illness, and disease-specific follow-up. ^{[40]A1b[90]C[91]D} The references supplied here support recognition of these monitoring domains but do not provide universal heart-rate or blood-pressure thresholds for beta-blocker adjustment. ^{[40]A1b[90]C[91]D}